Published On: Wed, Oct 19th, 2016

Life Technologies Corporation (NASDAQ:LIFE) Latest Broker Views


A number of investment brokers have recently updated their price targets on shares of Life Technologies Corporation (NASDAQ:LIFE).

Most recent broker ratings

04/11/2016 – BMO Capital Markets began new coverage on Life Technologies Corporation giving the company a “market perform” rating. They now have a USD 8 price target on the stock.

03/31/2016 – Life Technologies Corporation was downgraded to “market perform” by analysts at William Blair.

12/16/2015 – Citigroup began new coverage on Life Technologies Corporation giving the company a “neutral” rating.

11/11/2015 – Life Technologies Corporation had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 44 price target on the stock.

01/13/2014 – Life Technologies Corporation was upgraded to “buy” by analysts at Ned Davis Research.

11/20/2013 – Life Technologies Corporation had its “neutral” rating reiterated by analysts at Zacks. They now have a USD 79 price target on the stock.

10/11/2013 – Life Technologies Corporation was downgraded to “hold” by analysts at TheStreet.

The share price of Life Technologies Corporation (NASDAQ:LIFE) was up +1.85% during the last day of trading, with a day high of 2.75. 62409 shares were traded during the last session.

The stock’s 50 day moving average is 3.09 and its 200 day moving average is 3.18. The stock’s market capitalization is 65.22M. Life Technologies Corporation has a 52-week low of 2.48 and a 52-week high of 13.26.

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.